Her2 expression in prostatic cancer: a comparison with mammary carcinoma.

[1]  L. Tan,et al.  Her-2/neu and breast cancer. , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[2]  M. Meyers,et al.  Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. , 2001, Urology.

[3]  K. Schaefer,et al.  Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast , 2001, The Journal of pathology.

[4]  H. Scher.  HER2 in prostate cancer--a viable target or innocent bystander? , 2000, Journal of the National Cancer Institute.

[5]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[6]  Ming-Shyue Lee,et al.  Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells , 2000, Oncogene.

[7]  C. Cordon-Cardo,et al.  Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. , 1999, Cancer research.

[8]  J. Epstein,et al.  Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. , 1999, Human pathology.

[9]  S. Schwartz,et al.  Prognostic value of immunohistochemical expression of the c‐erbB‐2 oncoprotein in metastasic prostate cancer , 1999, International journal of cancer.

[10]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Gillespie,et al.  Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts. , 1999, The Journal of urology.

[12]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[13]  J. Ross,et al.  Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma , 1997, Cancer.

[14]  Y. Arai,et al.  c‐erbB‐2 oncoprotein: A potential biomarker of advanced prostate cancer , 1997, The Prostate.

[15]  W. Grizzle,et al.  Elevated serum levels of p105erbB‐2 in patients with advanced‐stage prostatic adenocarcinoma , 1996, International journal of cancer.

[16]  T. H. van der Kwast,et al.  Cytogenetic heterogeneity and histologic tumor growth patterns in prostatic cancer. , 1995, Cytometry.

[17]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.